To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Biogen is paying $7.2 billion to ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The drugmaker will again face ...

Biogen raised its full-year earnings forecast Thursday as cost-cutting and the rollout of new products, including the closely watched Alzheimer’s drug Leqembi, helped make up for declining sales of ...

Naomi Fried, Boston Children’s Hospital’s Chief Innovation Officer, is leaving the hospital to become Vice President of Medical Information, Innovation, and External Partnerships at Biogen Idec, ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

BOSTON (AP) — Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, ...

One of the most prominent biotech companies is consolidating Cambridge operations with a full-building lease at a new Kendall Square development. Biogen signed a 585K SF lease at the 75 Broadway St.

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a ...

Boston, MA - June 12: Chris Viehbacher, CEO of Biogen, right, speaks at a fireside chat with Meg Tirrell during the World Medical Innovation Forum. (Photo by Suzanne Kreiter/The Boston Globe via Getty ...